US2020215083A1PendingUtilityA1

Methods for Treating Heart Transplant Rejection

Assignee: BATTHYANY CARLOSPriority: Jan 24, 2018Filed: Mar 18, 2020Published: Jul 9, 2020
Est. expiryJan 24, 2038(~11.5 yrs left)· nominal 20-yr term from priority
A61K 31/192A61K 31/60A61K 45/06A61P 37/06A61P 29/00
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Current therapeutic approach to treating heart allotransplantation rejection focus on immunosuppression protocols that carry harmful side effects after chronic use, which include global immune depression to the patient. The present inventors have discovered alternative and synergistic protocols based on inhibiting NF-κB and NLRP3 inflammasome-dependent IL-1βrelease with nitrated NSAID derivatives.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating heart transplant rejection comprising administering to a subject in need thereof an effective amount of a compound of Formula I: 
       
         
           
           
               
               
           
         
       
     
     
         2 . The method of  claim 1 , further comprising administering one or more secondary therapeutic agents. 
     
     
         3 . The method of  claim 2 , wherein the one or more secondary therapeutic agents is selected from the group consisting of calcineurin inhibitors, corticosteroids, cytotoxic immunosuppressants, immunosuppressant antibodies, sirolimus derivatives, other immunosuppressants, and any combination thereof. 
     
     
         4 . A method of treating heart transplant rejection in a subject comprising administering to said subject a pharmaceutical composition comprised of an effective amount of a compound of Formula I: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, and a carrier. 
     
     
         5 . The method of  claim 4 , wherein the pharmaceutical composition further comprises one or more secondary therapeutic agents. 
     
     
         6 . The method of  claim 5 , wherein the one or more secondary therapeutic agents is selected from the group consisting of calcineurin inhibitors, corticosteroids, cytotoxic immunosuppressants, immunosuppressant antibodies, sirolimus derivatives, other immunosuppressants, and any combination thereof.

Join the waitlist — get patent alerts

Track US2020215083A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.